Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 2
2011 2
2012 2
2013 1
2014 8
2015 9
2016 11
2017 13
2018 15
2019 12
2020 19
2021 17
2022 14
2023 11
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Lee JD, et al. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
Pain Management and Substance Use Disorders.
Sowicz TJ, Compton P, Matteliano D, Oliver J, Strobbe S, St Marie B, Turner HN, Wilson M. Sowicz TJ, et al. Pain Manag Nurs. 2022 Dec;23(6):691-692. doi: 10.1016/j.pmn.2022.08.015. Epub 2022 Oct 3. Pain Manag Nurs. 2022. PMID: 36202737 Free PMC article.
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mehrjerdi M, Stotts AL, Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Lapham GT, Addis M, Bradley KA; PROUD Trial Collaborators; Ghiroli MM, Hamilton LK, Hu Y, LaHue JS, Loree AM, Murphy SM, Northrup TF, Shmueli-Blumberg D, Silva AJ, Weinstein ZM, Wong MT, Burganowski RP. Wartko PD, et al. JAMA Intern Med. 2023 Dec 1;183(12):1343-1354. doi: 10.1001/jamainternmed.2023.5701. JAMA Intern Med. 2023. PMID: 37902748 Free PMC article.
Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada.
Wendt DC, Marsan S, Parker D, Lizzy KE, Roper J, Mushquash C, Venner KL, Lam A, Swansburg J, Worth N, Sorlagas N, Quach T, Manoukian K, Bernett P, Radin SM. Wendt DC, et al. J Subst Abuse Treat. 2021 Feb;121:108165. doi: 10.1016/j.jsat.2020.108165. Epub 2020 Oct 9. J Subst Abuse Treat. 2021. PMID: 33097315 Free PMC article.
Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Luo SX, et al. JAMA Psychiatry. 2024 Jan 1;81(1):45-56. doi: 10.1001/jamapsychiatry.2023.3596. JAMA Psychiatry. 2024. PMID: 37792357 Free PMC article.
121 results